Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-BLU-5937 in Healthy Male Subjects
NCT05244759Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camlipixant in refractory chronic cough (RCC), sponsored by GSK. Primary endpoint: Mass balance recovery of total radioactivity in all excreta at 168 hours. Started Aug 2020; status: completed.
02
Drugs
camlipixant
03
Conditions
refractory chronic cough (RCC)
Beyond the preview
Go deeper on NCT05244759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05244759.